Navigation Links
Nventa Announces Positive Interim Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial
Date:3/26/2008

3 out of 4 Patients in Cohort 2 Demonstrate T-Cell Responses Indicating

Potential HspE7 Therapeutic Benefit

SAN DIEGO, March 26 /PRNewswire-FirstCall/ -- Nventa Biopharmaceuticals Corporation (TSX: NVN) today announced interim immunological data from the first two cohorts of its ongoing Phase 1 clinical trial of its lead product candidate, HspE7, in patients with cervical intraepithelial neoplasia, or CIN, a precursor to cervical cancer. Preliminary evaluation of biological samples collected from the study's first and second cohorts indicates that administration of HspE7 results in an E7-specific T-cell immune response. Independent research findings recently published in the journal Gynecologic Oncology by Jeffrey Weber, M.D., Ph.D., associate director for clinical research at the University of Southern California's Norris Comprehensive Cancer Center, demonstrated that such an immune response may be associated with objective clinical responses in patients with CIN. Accordingly, Nventa believes that HspE7 may successfully treat CIN by activating and enhancing the body's natural immune system.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080303/LAM023LOGO)

As previously reported, doses administered in both study cohorts were found to be safe and well tolerated, with no serious adverse events being reported in either group. Cohort 1 was designed to establish a baseline for the study with patients in this group being administered 500 mcg of HspE7 and 50 mcg of Poly-ICLC, a potent toll-like receptor 3 (TLR-3) adjuvant. Consistent with previous preclinical studies conducted by Nventa, this dose level demonstrated anti-HspE7 antibody responses but limited T-cell responses. In cohort 2, patients were administered 500 mcg of HspE7 and 500 mcg of Poly-ICLC. In this group, 3 out of 4 patients showed anti-HspE7 antibody responses and HPV16 E7-speci
'/>"/>

SOURCE Nventa Biopharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Nventa Enrolls and Initiates Dosing of Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
2. Nventa Evaluation Complete for First Three Cohorts in HspE7 Phase 1 Cervical Dysplasia Trial
3. Anacor Pharmaceuticals Announces Positive Results from Phase 2a Clinical Trial of AN2728 in Psoriasis Patients
4. Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
5. IDM Pharma Announces Availability of Mifamurtide (L-MTP-PE) Through Compassionate Access Study
6. Valor Medical Announces First Human Implant of Neucrylate AN(TM) for Treatment of Cerebral Aneurysm
7. Medicare Announces Expanded Coverage for Anticoagulation Patients, Opening the Door for More Patients to Test PT/INR at Home
8. Medicare Announces Expanded Coverage for Warfarin Patients Monitoring Clotting Time at Home
9. FluoroPharma Announces Commencement of Phase I Clinical Trial for BFPET(TM), Myocardial Perfusion Imaging (MPI) Tracer for Positron Emission Tomography (PET)
10. Emisphere Announces Second Study Demonstrating Dramatic Increases in Absorption of Oral B12 Using eligen(R) Technology at Lower Doses
11. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... 2014 Leading events organizer UBM Live ... the seventh year to São Paulo, Brazil ... 2014. The event will co-locate with Food Ingredients South America ... meeting point for the pharmaceutical industry.      (Logo: ... pharmaceutical sales are now exploring the South America ...
(Date:7/24/2014)... July 24, 2014   AcelRx Pharmaceuticals, Inc.  (Nasdaq: ... on the development and commercialization of innovative therapies for ... the PDUFA date for Zalviso remains July 27, 2014.  ... circulated online stating the Food and Drug Administration (FDA) ... has been no notification to the company from the ...
(Date:7/24/2014)... , Deutschland, und MARSEILLE ... -- , Weltweite ... ermöglicht QIAGEN die Entwicklung von Tests ... für Blutkrebs  Neuer Test weist ... mit Knochenmarkserkrankungen (myelodysplastischen Syndromen) einen günstigen Krankheitsverlauf ...
Breaking Medicine Technology:CPhI South America 2014 Launches with Generics Showing Huge Growth 2CPhI South America 2014 Launches with Generics Showing Huge Growth 3CPhI South America 2014 Launches with Generics Showing Huge Growth 4AcelRx Pharmaceuticals Confirms July 27, 2014 PDUFA Date for Zalviso 2QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 2QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 3QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 4QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 5
... 2011 Orexigen ® Therapeutics, Inc. (Nasdaq: OREX ... Securities Healthcare Conference in New York. The presentation is scheduled for ... listen to the live webcast or a replay of the presentation, ... at www.orexigen.com . A replay will be available for 14 ...
... MONMOUTH JUNCTION, N.J., Sept. 26, 2011 Insmed Incorporated (Nasdaq ... President and CEO of Insmed, will be presenting a corporate ... Wednesday, September 28, 2011, at 11:30 AM ET, in New ... available on Insmed,s website, http://www.insmed.com .  The webcast will ...
Cached Medicine Technology:Insmed to Present at Sixth Annual JMP Securities Healthcare Conference 2
(Date:7/28/2014)... (PRWEB) July 28, 2014 As health ... are looking to private exchanges. “Private Exchange Strategies ... 6 webinar from Atlantic Information Services, will provide answers ... exchange strategies for the future. , Barbara Gniewek, Jonathan ... with extensive experience in the private exchange sector — ...
(Date:7/28/2014)... According to the Drama Method Pdf review recently updated ... women easily get the attention of the men they want ... review that this book can teach ladies how to become ... also instructs them how to conquer a man, and get ... review that this book is divided into 30 chapters including: ...
(Date:7/28/2014)... Calif., July 27, 2014 - (PRWEB) July 28, 2014 ... in 12 months by earning the Masters Champion title at ... proving that age is no obstacle for this athlete. She ... at the event hosted by the International Pole Sports Federation ... 63, traveling from 30 countries, took part in the competition. ...
(Date:7/28/2014)... 2014 In The Tainted ... market to a disadvantaged consumer base, be ... proven, often offensive, ethnically-slanted advertisements to bombard ... Tainted Burger." Amazon: http://www.amazon.com/s/ref=nb_sb_noss?url=search-alias%3Daps&field-keywords=tainted%20burger .) ... author and activist who says, "So what ...
(Date:7/27/2014)... Hyaluronic Acid can hold 1,000 times ... to the power of Hyaluronic Serums. , "Hyaluronic acid ... of Sublime Beauty®. "But like collagen, it diminishes with ... improves skin moisture-retention and radiance." , Hyaluronic acid ... healthy and beautiful look. Key Ingredients in the serum ...
Breaking Medicine News(10 mins):Health News:Three PwC Consultants to Offer Insurers Successful Strategies for Private Exchanges 2Health News:The Drama Method Pdf Review Exposes Aaron Fox's Relationship Guide – Vkool.com 2Health News:The Drama Method Pdf Review Exposes Aaron Fox's Relationship Guide – Vkool.com 3Health News:Inspiring Senior Athlete Lands Third World Title in One Year 2Health News:The Tainted Burger- McDonalds's Franchise Owner's Tale by Author Michael B. Potts Says McDonald's Disproportionately Markets to Minorities--Tedx Video Supports Claim 2Health News:Aging or Dry Skin Benefits from Hyaluronic Serum; Now 30% Off Sale at Sublime Beauty® 2
... has been conferred the honor of CBE in the Queens ... in UK , was first diagnosed with breast cancer when ... to haunt her a decade later, spreading to her lungs ... told six years ago. ,But undaunted she has ...
... ,Sometime ago a nurse in UK was found screaming at a ... urine . And now it is reported that a quarter of ... them. ,However, the Healthcare Commission said 40% of trusts ... year. In total there are 24 core NHS standards, covering everything ...
... plans for its survival, some tourists and locals are setting ... out tonnes of garbage that threatens to choke the ... and domestic tourists, houseboat owners and voluntary groups collected truckloads ... from the lake Monday. ,The effort to clean ...
... rules to dissuade erring doctors and hospitals involved in ... of the organs being sourced from death-row prisoners ... which prohibits sale of human organs. , ,Organ ... transplants has resulted in many counties making this form of ...
... will give lifelong benefit to patients and it is also ... . ,Compared to traditional jabs, the new FLU-v vaccine ... a global epidemic. "We expect one course of injections - ... immunity," the Daily Mail quoted Dr Stuart Robinson of the ...
... with a computer's worst enemy: heat . ,Too much ... to become slower and less stable. A hot day combined with ... the end of a computer altogether. ,But there are ... the summertime. By paying attention to how much heat-stress your PC ...
Cached Medicine News:Health News:42-year-old Cancer Patient Honored by British Queen for Her Fundraising Efforts 2Health News:UK Hospitals Failing Hygiene Standards 2Health News:Volunteers Remove Garbage from Kashmir's Dal Lake 2Health News:China to Curtail Organ Sale 2Health News:China to Curtail Organ Sale 3Health News:Hot Tips for Keeping Your PC Cool in Summer 2Health News:Hot Tips for Keeping Your PC Cool in Summer 3
Determination of Prothrombin Time (PT)by STA Analyzers (ISI~1.8).Freeze-dried rabbit brain thromboplastin with heparin inhibitor....
The CA method used on the Dade Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of calcium in serum....
The PHOS method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of phosphorus in serum....
For the quantitative in vitro determination of Magnesium in serum, plasma and urine...
Medicine Products: